CANN GROUP LIMITED — Board/Management Information 2021

Apr 26, 2021

==> picture [105 x 41] intentionally omitted <==

ASX ANNOUNCEMENT

27 April 2021

John Sharman appointed to the board of Cann Group

27 April 2021 – Cann Group Limited (ASX: CAN) ( Cann or the Company ) announced today that Mr John Sharman has been appointed to the Board of Directors, with the appointment taking effect today. Mr Sharman’s appointment will be confirmed by shareholders at the Company’s AGM scheduled for November 2021.

Mr Sharman has extensive international business experience as a Managing Director, CEO, CFO and non-executive director with public and private companies, including several ASX listed entities. He has a comprehensive understanding of the medical manufacturing industry as well as the pharmaceutical and nutraceutical sectors. He has led businesses with operations in Australia, the UK, Europe, Asia and the USA, building distribution, sales, marketing and manufacturing networks both locally and internationally.

Cann Group Chairman Allan McCallum AO, said the appointment of Mr Sharman as a director was an important step in the growth of Cann.

“The ability to attract a director of John’s strength and experience to our Board, which complements our existing skill base, is key to the next phase of Cann as we move ahead with the construction and commissioning of our Mildura facility, de-risking our supply chain and increasing our revenue from Satipharm and other products.”

Mr Sharman is currently the CEO of Universal Biosensors Inc (ASX:UBI). Prior to that he served 10 years as CEO of Medical Developments International (ASX:MVP). Previous roles included Managing Director of CVC Venture Managers (private equity managers), Managing Director of Vita Life Sciences (ASX:VSC) and Cyclopharm (ASX:CYC), as well as roles at PriceWaterhouseCoopers, National Australia Bank and KPMG in both London and Melbourne. He has a Bachelor of Economics from Monash University and a Master of Applied Finance from Macquarie University. He is a Member of the Institute of Chartered Accountants in Australia and a Member of the Australian Institute of Company Directors.

Cann Group Limited ACN 603 949 739 4 Research Avenue, Bundoora, VIC 3083 Australia Ph: +61 3 9095 7088

==> picture [78 x 31] intentionally omitted <==

Authorised for release by the Board of Directors of Cann Group Limited.

For all media enquiries please contact:

Matthew Wright NWR Communications +61 451 896 420 matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock Clive Fanning CEO Head of Investor Relations Cann Group Limited Cann Group Limited +61 3 9095 7088 +61 3 9095 7088 contact@canngrouplimited.com clive.fanning@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouplimited.com | www.satipharm.com

2